Article Sidebar

Submitted
4 August 2024
Accepted
9 September 2024
Published
10 September 2024
Download
PDF
Statistic
Read Counter : 108 Download : 28

Main Article Content

Abstract

Highlights:
1. This study provides a comprehensive analysis of various factors such as age, sex, education, occupation, BMI, and comorbidities, and their relationship with bacterial infections in COPD patients experiencing exacerbation and type 2 respiratory failure.
2. While the COPD patients experiencing exacerbation did not exhibit resistance to linezolid and vancomycin, they demonstrated specific antibiotic resistance patterns characterized by high resistance rates to commonly used antibiotics such as meropenem and amikacin.
3. The findings enhance the understanding of the complex interplay of factors influencing infection patterns in this patient population.


 


Abstract


Chronic obstructive pulmonary disease (COPD) is a prevalent condition characterized by persistent respiratory symptoms and airflow limitation. Bacterial infections may trigger COPD exacerbations, leading to more severe symptoms as well as increased morbidity and mortality rates. This study aimed to investigate the bacterial profiles and antibiotic resistance in COPD patients who had experienced exacerbation and type 2 respiratory failure at Adam Malik Central General Hospital, Medan, Indonesia. This retrospective study utilized medical records spanning from January 1, 2020, to December 1, 2022. The sample included patients aged 40–90 years who had experienced COPD exacerbation and type 2 respiratory failure. The exclusion criteria were patients who had received antibiotic therapy within 48 hours before admission, were severely immunocompromised, and had severe malignancy. The analysis results were presented in the form of means, standard deviations, and frequency distributions. Additionally, an analysis of the relationship between the categorical variables was performed using the Chi-squared test (p<0.05). The study analyzed 25 subjects with an average age of 63.6 years, primarily consisting of men (84%). It was shown that severe exacerbations were prevalent (92%), accompanied by the presence of common comorbidities including pneumonia (52%), diabetes mellitus (32%), and other non-communicable diseases (44%). Bacterial growth was observed in 76% of the subjects, predominantly involving Gram-negative bacteria (89.4%). Klebsiella pneumoniae (26.3%) and Pseudomonas aeruginosa (21.1%) were the most frequently isolated species. The antibiotic resistance patterns indicated that meropenem and amikacin had the highest resistance rates (100%). Cefepime, ertapenem, and gentamicin exhibited notable resistance rates of 66.7%, 66.7%, and 75.0%, respectively. This study highlights the high prevalence of Gram-negative bacteria and significant antibiotic resistance in COPD patients who exhibit exacerbation and type 2 respiratory failure.

Keywords

Chronic obstructive pulmonary disease chronic respiratory diseases infectious disease

Article Details

License

Copyright (c) 2024 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Lia Mutia Annisa, Fajrinur Syarani, Andika Pradana, & Erna Mutiara. (2024). Bacterial Profiles and Antibiotic Resistance in Chronic Obstructive Pulmonary Disease Patients with Exacerbation and Type 2 Respiratory Failure at Adam Malik General Hospital. Folia Medica Indonesiana, 60(3), 216–223. https://doi.org/10.20473/fmi.v60i3.61441
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Avery LM, Nicolau DP (2018). Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opinion on Investigational Drugs 27, 325–338. doi: 10.1080/13543784.2018.1460354.
  2. Bassetti M, Vena A, Giacobbe DR, et al (2021). Management of infections caused by multidrug-resistant gram-negative pathogens: Recent advances and future directions. Archives of Medical Research 52, 817–827. doi: 10.1016/j.arcmed.2021.09.002.
  3. Bassetti S, Tschudin-Sutter S, Egli A, et al (2022). Optimizing antibiotic therapies to reduce the risk of bacterial resistance. European Journal of Internal Medicine 99, 7–12. doi: 10.1016/j.ejim.20 22.01.029.
  4. Bender RG, Sirota SB, Swetschinski LR, et al (2024). Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet Infectious Diseases 24, 974–1002. doi: 10.1016/S1473-3099(24)00176-2.
  5. Buttery SC, Zysman M, Vikjord SAA, et al (2021). Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity. Respirology 26, 419–441. doi: 10.1111/resp.14032.
  6. Celli BR, Fabbri LM, Aaron SD, et al (2021). An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The rome proposal. American Journal of Respiratory and Critical Care Medicine 204, 1251–1258. doi: 10.1164/rccm.202108-1819PP.
  7. Dicker AJ, Huang JTJ, Lonergan M, et al (2021). The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology 147, 158–167. doi: 10.1016/j.jaci.20 20.02.040.
  8. Dima E, Kyriakoudi A, Kaponi M, et al (2019). The lung microbiome dynamics between stability and exacerbation in chronic obstructive pulmonary disease (COPD): Current perspectives. Respiratory Medicine 157, 1–6. doi: 10.1016/j.rme d.2019.08.012.
  9. Grahn K, Gustavsson P, Andersson T, et al (2021). Occupational exposure to particles and increased risk of developing chronic obstructive pulmonary disease (COPD): A population-based cohort study in Stockholm, Sweden. Environmental Research 200, 111739. doi: 10.1016/j.envres.2021.111739.
  10. Gupta N, Haley R, Gupta A, et al (2020). Chronic obstructive pulmonary disease in the intensive care unit: Antibiotic treatment of severe chronic obstructive pulmonary disease exacerbations. Seminars in Respiratory and Critical Care Medicine 41, 830–841. doi: 10.1055/s-0040-1708837.
  11. IBM Corp (2017). IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp. Available at: https://www.ibm.com/support/pages /downloading-ibm-spss-statistics-25.
  12. Ji Z, de Miguel-Díez J, Castro-Riera CR, et al (2020). Differences in the outcome of patients with COPD according to body mass index. Journal of Clinical Medicine 9, 710. doi: 10.3390/jcm90307 10.
  13. Kaleem Ullah M, Malamardi S, Siddaiah JB, et al (2022). Trends in the bacterial prevalence and antibiotic resistance patterns in the acute exacerbation of chronic obstructive pulmonary disease in hospitalized patients in South India. Antibiotics 11, 1577. doi: 10.3390/antibiotics1111 1577.
  14. Kavipriya D, Prakash SS, Dhandapani S, et al (2021). Evaluation of the performance of direct susceptibility test by VITEK-2 from positively flagged blood culture broth for gram-negative bacilli. Journal of Laboratory Physicians 13, 374–9. doi: 10.1055/s-0041-1732489.
  15. Liu Y, Zhang Y, Zhao W, et al (2019). Pharmacotherapy of lower respiratory tract infections in elderly—focused on antibiotics. Frontiers in Pharmacology. doi: 10.3389/fphar.20 19.01237.
  16. Lius EE, Syafaah I (2022). Hyperoxia in the management of respiratory failure: A literature review. Annals of Medicine & Surgery. doi: 10.1016/j.amsu.2022.104393.
  17. Ma Y, Huang K, Liang C, et al (2021). Real-world antibiotic use in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China: Evidence from the ACURE study. Frontiers in Pharmacology. doi: 10.3389/fphar.2021.649884.
  18. MacLeod M, Papi A, Contoli M, et al (2021). Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology 26, 532–551. doi: 10.1111/resp.14041.
  19. Moghoofei M, Azimzadeh Jamalkandi S, Moein M, et al (2020). Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Infection 48, 19–35. doi: 10.1007/s15010-019-01350-1.
  20. Neder JA, Berton DC, Phillips DB, et al (2021). Exertional ventilation/carbon dioxide output relationship in COPD: From physiological mechanisms to clinical applications. European Respiratory Review 30, 200190. doi: 10.1183/16000617.0190-2020.
  21. Peltola L, Pätsi H, Harju T (2020). COPD comorbidities predict high mortality – asthma-COPD-overlap has better prognosis. COPD: Journal of Chronic Obstructive Pulmonary Disease 17, 366–372. doi: 10.1080/15412555.202 0.1783647.
  22. Poureslami I, Tregobov N, Shum J, et al (2021). A conceptual model of functional health literacy to improve chronic airway disease outcomes. BMC Public Health 21, 252. doi: 10.1186/s12889-021-10313-x.
  23. Rana R, Singhal R (2015). Chi-square test and its application in hypothesis testing. Journal of the Practice of Cardiovascular Sciences 1, 69. doi: 10.4103/2395-5414.157577.
  24. Roversi S, Corbetta L, Clini E (2017). GOLD 2017 recommendations for COPD patients: Toward a more personalized approach. COPD Research and Practice 3, 5. doi: 10.1186/s40749-017-0024-y.
  25. Spece LJ, Epler EM, Donovan LM, et al (2018). Role of comorbidities in treatment and outcomes after chronic obstructive pulmonary disease exacerbations. Annals of the American Thoracic Society 15, 1033–1038. doi: 10.1513/AnnalsATS .201804-255OC.
  26. Vlahovich KP, Sood A (2021). A 2019 update on occupational lung diseases: A narrative review. Pulmonary Therapy 7, 75–87. doi: 10.1007/s410 30-020-00143-4.
  27. Vogelmeier CF, Román-Rodríguez M, Singh D, et al (2020). Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory Medicine 166, 105938. doi: 10.1016/j.rmed.2020. 105938.
  28. Westerik JAM, Metting EI, van Boven JFM, et al (2017). Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respiratory Research 18, 31. doi: 10.1186/s12931-017-0512-2.
  29. Zhou M, Wang Y, Liu C, et al (2018). Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals. Infection and Drug Resistance 11, 1347–1158. doi: 10.2147/IDR.S166790.